Drug Profile
Research programme: locked nucleic acid oligonucleotides - Boehringer Ingelheim/Roche
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Roche
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Germany (PO)
- 28 Jan 2022 No recent reports of development identified for research development in Inflammatory-bowel-diseases in Switzerland (PO)
- 19 Dec 2017 Boehringer Ingelheim and Roche enter into a collaboration agreement for the development of locked nucleic acid oligonucleotides for Inflammatory bowel diseases